A single-arm, multicenter phase 2 ROAR trial (NCT02034110) elucidated the activity of the BRAF/MEK inhibitor combination in the context of CCA by evaluating the BRAF inhibitor dabrafenib (Tafinlar) combined with the MEK inhibitor trametinib (Mekinist) [45]. Here, MAP2K7 is linked to cholangiocarcinoma.